TTI-101
Tvardi Therapeutics
['solid tumor']
 #aimhi portfolio company, tvardi therapeutics unveils promising phase 1 data on tti-101, a stat3 inhibitor, at #asco2023! the groundbreaking results highlight safety, tolerability, and clinical activity in advanced solid tumors. learn more: 
Supporting start-up oncology companies and bridging cancer discoveries from bench to bedside!